Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: A study of polymorphisms in the adenosine pathway

Annals of the Rheumatic Diseases

Volumn 69, Issue 5, 2010, Pages 931-932

  Grabar, Petra Bohanec ^a   Rojko, Sabina ^a   Logar, Dušan ^b   Dolžan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

DISEASE ACTIVITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADENOSINE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951517865     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.111567     Document Type: Letter

References (8)

1. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-2774 (Pubitemid 39209513)
2. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-3103 (Pubitemid 44622078)
3. Lee YC, Cui J, Costenbader KH, et al. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) 2009;48:613-617
4. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-612
5. Wessels JA, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-2839 (Pubitemid 44497761)
6. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-1775
7. Bohanec Grabar P, Logar D, Lestan B, et al. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008;64:1057-1068
8. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-1850